M0223 Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the ... more covid-19 public health emergency
HCPCS Procedure & Supply Codes
Code Added 2022-02-11: Code added. FDA authorized EUA.
M0223 - Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information.
Access to this feature is available in the following products:
Find-A-Code Essentials
HCC Plus
Find-A-Code Professional
Find-A-Code Facility Base
The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information.
Additional Code Information (Global Days, MUEs, etc.)
Additional Code Information includes:
APC Status Indicator
Assistant Surgeon (80, 82)
Bilateral Surgery (50)
CCS Clinical Classification
Co-Surgeons (62)
Diagnostic Imaging Family
Facility MUEs
Global Days
Hierarchical Condition Categories (HCC)
Major Complications or Comorbidities (MCC/CC)
Medicare Status Code
Multiple Procedures (51)
Non-Facility MUEs
OTS Orthotic
PC/TC Indicator (26)
Physician Supervisions
Team Surgery (66)
Type Of Service (TOS)
and more...
Access to this feature is available in the following products:
HCC Plus
Find-A-Code Professional
Find-A-Code Facility Base
Top Modifiers - Most Often Billed
Save time with a Professional or Facility subscription! You will be able to see the most common modifiers billed to Medicare along with this code.
Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency
$550.50
2022-02-11
TBD
[3][11]
(your fee)
[3] These rates will be geographically adjusted for many providers.
[11] On November 30, 2022, the FDA announced that bebtelovimab isn’t currently authorized in any U.S. region because it isn’t expected to neutralize Omicron sub-variants BQ.1 and BQ.1.1. Therefore, you may not administer bebtelovimab to treat COVID-19 under the EUA until further notice.
Quick, Current, Complete - www.findacode.com